UnknownPhase 2NCT00490789

Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cardiff University
Principal Investigator
Julian R Sampson, DM
Cardiff Univeristy
Intervention
sirolimus(drug)
Enrollment
14 enrolled
Eligibility
18-65 years · All sexes
Timeline
20052009

Study locations (3)

Collaborators

University of Nottingham · St Georges Hospital Medical School · Royal Sussex County Hospital · The Tuberous Sclerosis Association · Wyeth is now a wholly owned subsidiary of Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00490789 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials